Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once-weekly versus placebo in drug-naive adults with type 2 diabetes
2013-000632-94Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-000632-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000632-94.